

Joseph S. Ross

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6806430/joseph-s-ross-publications-by-year.pdf>

Version: 2024-04-04

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150 papers	8,524 citations	42 h-index	91 g-index
165 ext. papers	10,063 ext. citations	13.8 avg, IF	5.98 L-index

#	Paper	IF	Citations
150	Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults.. <i>Endocrine</i> , 2022 , 1	4	0
149	A multicenter evaluation of computable phenotyping approaches for SARS-CoV-2 infection and COVID-19 hospitalizations.. <i>Npj Digital Medicine</i> , 2022 , 5, 27	15.7	0
148	Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA. <i>Trials</i> , 2021 , 22, 817	2.8	1
147	Clinical studies sponsored by digital health companies participating in the FDA's Precertification Pilot Program: A cross-sectional analysis. <i>Clinical Trials</i> , 2021 , 17407745211048493	2.2	
146	Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020. <i>Journal of General Internal Medicine</i> , 2021 , 1	4	0
145	Accuracy of Computable Phenotyping Approaches for SARS-CoV-2 Infection and COVID-19 Hospitalizations from the Electronic Health Record 2021 ,		4
144	Medicare's New Device-Coverage Pathway - Breakthrough or Breakdown?. <i>New England Journal of Medicine</i> , 2021 , 384, e43	59.2	2
143	US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018. <i>Clinical Trials</i> , 2021 , 18, 488-499	2.2	7
142	Leveraging Open Science to Accelerate Research. <i>New England Journal of Medicine</i> , 2021 , 384, e61	59.2	6
141	Direct-to-consumer personal genomic tests need better regulation. <i>Nature Medicine</i> , 2021 , 27, 940-943	50.5	3
140	Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use. <i>Endocrine</i> , 2021 , 74, 592-602	4	1
139	Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation. <i>Clinical Trials</i> , 2021 , 18, 732-740	2.2	1
138	Characteristics of available studies and dissemination of research using major clinical data sharing platforms. <i>Clinical Trials</i> , 2021 , 18, 657-666	2.2	3
137	Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e008040	5.8	
136	Assessment of Preprint Policies of Top-Ranked Clinical Journals. <i>JAMA Network Open</i> , 2020 , 3, e2011127	10.4	14
135	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 734-745	27.4	132
134	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. <i>Journal of the American Heart Association</i> , 2020 , 9, e013606	6	3

133	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. <i>Thrombosis Research</i> , 2020 , 186, 78-79	8.2	2
132	Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. <i>Npj Digital Medicine</i> , 2020 , 3, 60	15.7	22
131	Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trials-a brave new world. <i>Clinical Trials</i> , 2020 , 17, 243-246	2.2	2
130	Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. <i>JAMA Network Open</i> , 2020 , 3, e203284	10.4	31
129	Evaluation of the Anticipated Burden of COVID-19 on Hospital-Based Healthcare Services Across the United States 2020 ,		8
128	Confidentiality Orders and Public Interest in Drug and Medical Device Litigation. <i>JAMA Internal Medicine</i> , 2020 , 180, 292-299	11.5	2
127	Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA. <i>Trials</i> , 2020 , 21, 675	2.8	7
126	Early experience with the FDA's Breakthrough Devices program. <i>Nature Biotechnology</i> , 2020 , 38, 933-938	14.5	9
125	Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials. <i>Clinical Trials</i> , 2020 , 17, 723-728	2.2	
124	Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics. <i>Journal of General Internal Medicine</i> , 2020 , 35, 1928-1930	4	3
123	Time for NIH to lead on data sharing. <i>Science</i> , 2020 , 367, 1308-1309	33.3	18
122	Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures. <i>PLoS ONE</i> , 2020 , 15, e0230734	3.7	1
121	Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals. <i>Circulation</i> , 2019 , 140, 379-389	16.7	14
120	Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2305-2314	5.6	12
119	Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition. <i>JAMA Internal Medicine</i> , 2019 , 179, 686-693	11.5	21
118	Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015. <i>Milbank Quarterly</i> , 2019 , 97, 796-819	3.9	12
117	Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies. <i>Journal of General Internal Medicine</i> , 2019 , 34, 2319-2321	4	1
116	Modernizing the FDA's 510(k) Pathway. <i>New England Journal of Medicine</i> , 2019 , 381, 1891-1893	59.2	13

115	Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation. <i>BMJ Open</i> , 2019 , 9, e025936	3	
114	Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017. <i>Research Integrity and Peer Review</i> , 2019 , 4, 26	6.1	1
113	Generic Drugs in the United States: Policies to Address Pricing and Competition. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 329-337	6.1	9
112	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. <i>JAMA Internal Medicine</i> , 2019 , 179, 263-265	11.5	6
111	Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines. <i>Journal of General Internal Medicine</i> , 2018 , 33, 651-658	4	13
110	Defining Multiple Chronic Conditions for Quality Measurement. <i>Medical Care</i> , 2018 , 56, 193-201	3.1	7
109	Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 562-569	4.7	15
108	The Impact of Off-Patent Drug Acquisitions on Prices. <i>Journal of General Internal Medicine</i> , 2018 , 33, 1007-1009	4	1
107	Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators. <i>Annals of Internal Medicine</i> , 2018 , 169, 586-588	8	4
106	Patterns and predictors of off-label prescription of psychiatric drugs. <i>PLoS ONE</i> , 2018 , 13, e0198363	3.7	25
105	Age of Data at the Time of Publication of Contemporary Clinical Trials. <i>JAMA Network Open</i> , 2018 , 1, e181065	10.4	14
104	Overview and experience of the YODA Project with clinical trial data sharing after 5 years. <i>Scientific Data</i> , 2018 , 5, 180268	8.2	33
103	New and incremental FDA black box warnings from 2008 to 2015. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 117-123	4.1	17
102	Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. <i>BMJ Open</i> , 2018 , 8, e021685	3	0
101	Emergency Department Volume and Outcomes for Patients After Chest Pain Assessment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004683	5.8	13
100	Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. <i>Trials</i> , 2018 , 19, 581	2.8	16
99	Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia: An Analysis of Within- and Between-Hospital Variation. <i>JAMA Network Open</i> , 2018 , 1, e182044	10.4	28
98	Fulfilling the Promise of Unique Device Identifiers. <i>Annals of Internal Medicine</i> , 2018 , 169, 183-185	8	12

97	Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 848-856	2.6	1
96	Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 1854-1863	27.4	164
95	Hospital Characteristics Associated With Risk-standardized Readmission Rates. <i>Medical Care</i> , 2017 , 55, 528-534	3.1	35
94	Having Their Cake and Eating It Too: Physician Skepticism of the Open Payments Program. <i>American Journal of Bioethics</i> , 2017 , 17, 19-22	1.1	2
93	Regulatory Review of New Therapeutic Agents - FDA versus EMA, 2011-2015. <i>New England Journal of Medicine</i> , 2017 , 376, 1386-7	59.2	29
92	Merits of Data Sharing: The Digitalis Investigation Group Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1825-1827	15.1	6
91	Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. <i>Trials</i> , 2017 , 18, 333	2.8	32
90	Hospital-Readmission Risk - Isolating Hospital Effects from Patient Effects. <i>New England Journal of Medicine</i> , 2017 , 377, 1055-1064	59.2	72
89	Quality of Care in the United States Territories, 1999-2012. <i>Medical Care</i> , 2017 , 55, 886-892	3.1	0
88	Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 270-278	27.4	127
87	Data Sharing and Cardiology: Platforms and Possibilities. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 3018-3025	15.1	5
86	Regulatory Review of New Therapeutic Agents. <i>New England Journal of Medicine</i> , 2017 , 376, 2598	59.2	8
85	Data Desert for Inferior Vena Caval Filters: Limited Evidence, Supervision, and Research. <i>JAMA Cardiology</i> , 2017 , 2, 3-4	16.2	11
84	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. <i>Diabetes Care</i> , 2017 , 40, 468-475	14.6	181
83	A Nationwide Assessment of the Association of Smoking Bans and Cigarette Taxes With Hospitalizations for Acute Myocardial Infarction, Heart Failure, and Pneumonia. <i>Medical Care Research and Review</i> , 2017 , 74, 687-704	3.7	9
82	US drug marketing: how does promotion correspond with health value?. <i>BMJ, The</i> , 2017 , 357, j1855	5.9	25
81	Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015. <i>Ophthalmology</i> , 2017 , 124, 1237-1246	7.3	0
80	Characterisation of trials where marketing purposes have been influential in study design: a descriptive study. <i>Trials</i> , 2016 , 17, 31	2.8	23

79	Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals. <i>Trials</i> , 2016 , 17, 199	2.8	49
78	Availability of Clinical Trial Data From Industry-Sponsored Cardiovascular Trials. <i>Journal of the American Heart Association</i> , 2016 , 5, e003307	6	12
77	Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 582-92	27.4	59
76	Risk-standardized Acute Admission Rates Among Patients With Diabetes and Heart Failure as a Measure of Quality of Accountable Care Organizations: Rationale, Methods, and Early Results. <i>Medical Care</i> , 2016 , 54, 528-37	3.1	9
75	Commentary: Diagnostic devices in clinical trials have high stakes for patient care. <i>BMJ, The</i> , 2016 , 354, i5197	5.9	1
74	Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 2647-2656	27.4	175
73	Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study. <i>Annals of Internal Medicine</i> , 2016 , 165, 20-29	8	45
72	Comparative Effectiveness of Generic Atorvastatin and Lipitor [®] in Patients Hospitalized with an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2016 , 5, e003350	6	23
71	Decision-making and cancer screening: a qualitative study of older adults with multiple chronic conditions. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 93-100	3.6	19
70	Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugs. <i>Health Affairs</i> , 2015 , 34, 681-8	7	7
69	Poorly cited articles in peer-reviewed cardiovascular journals from 1997 to 2007: analysis of 5-year citation rates. <i>Circulation</i> , 2015 , 131, 1755-62	16.7	26
68	Variation in US hospital emergency department admission rates by clinical condition. <i>Medical Care</i> , 2015 , 53, 237-44	3.1	53
67	Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 740-1	64.1	8
66	Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 604-12	27.4	59
65	Development and Validation of an Algorithm to Identify Planned Readmissions From Claims Data. <i>Journal of Hospital Medicine</i> , 2015 , 10, 670-7	2.7	43
64	National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011. <i>Journal of the American Heart Association</i> , 2015 , 4, e001718	6	6
63	Usual source of care and outcomes following acute myocardial infarction. <i>Journal of General Internal Medicine</i> , 2014 , 29, 862-9	4	14
62	Impact of drug policy on regional trends in ezetimibe use. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 589-96	5.8	7

61	Physician clinical management strategies and reasoning: a cross-sectional survey using clinical vignettes of eight common medical admissions. <i>BMC Health Services Research</i> , 2014 , 14, 176	2.9	3
60	Hospital variation in risk-standardized hospital admission rates from US EDs among adults. <i>American Journal of Emergency Medicine</i> , 2014 , 32, 837-43	2.9	20
59	Transfer rates from nonprocedure hospitals after initial admission and outcomes among elderly patients with acute myocardial infarction. <i>JAMA Internal Medicine</i> , 2014 , 174, 213-22	11.5	14
58	Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey. <i>Trials</i> , 2014 , 15, 384	2.8	19
57	Reporting of results in ClinicalTrials.gov and high-impact journals. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1063-5	27.4	62
56	Place of residence and outcomes of patients with heart failure: analysis from the telemonitoring to improve heart failure outcomes trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 749-56	5.8	46
55	Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 368-77	27.4	244
54	National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. <i>JAMA Internal Medicine</i> , 2014 , 174, 1116-24	11.5	270
53	Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. <i>JAMA Internal Medicine</i> , 2014 , 174, 1486-93	11.5	16
52	Payments for acute myocardial infarction episodes-of-care initiated at hospitals with and without interventional capabilities. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 882-8	5.8	3
51	Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis. <i>JAMA Internal Medicine</i> , 2014 , 174, 1176-82	11.5	10
50	Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. <i>American Heart Journal</i> , 2014 , 167, 683-9	4.9	14
49	Hospital-based, acute care use among patients within 30 days of discharge after coronary artery bypass surgery. <i>Annals of Thoracic Surgery</i> , 2013 , 96, 96-104	2.7	30
48	Ushering in a new era of open science through data sharing: the wall must come down. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1355-6	27.4	77
47	When choosing statin therapy: the case for generics. <i>JAMA Internal Medicine</i> , 2013 , 173, 229-32	11.5	14
46	Regional density of cardiologists and rates of mortality for acute myocardial infarction and heart failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013 , 6, 352-9	5.8	20
45	Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 355-63	27.4	653
44	Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 587-93	27.4	256

43	Time to publication among completed clinical trials. <i>JAMA Internal Medicine</i> , 2013 , 173, 825-8	11.5	64
42	Financial stress and outcomes after acute myocardial infarction. <i>PLoS ONE</i> , 2012 , 7, e47420	3.7	22
41	Regulatory review of novel therapeutics--comparison of three regulatory agencies. <i>New England Journal of Medicine</i> , 2012 , 366, 2284-93	59.2	118
40	Coronary artery bypass graft: contemporary heart surgery center performance in China. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 214-21	5.8	12
39	Based on key measures, care quality for Medicare enrollees at safety-net and non-safety-net hospitals was almost equal. <i>Health Affairs</i> , 2012 , 31, 1739-48	7	39
38	The importance of clinical trial data sharing: toward more open science. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 238-40	5.8	56
37	State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. <i>Health Affairs</i> , 2012 , 31, 188-98	7	12
36	Generic atorvastatin and health care costs. <i>New England Journal of Medicine</i> , 2012 , 366, 201-4	59.2	46
35	Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. <i>BMJ, The</i> , 2012 , 344, d7292	5.9	238
34	Promoting transparency in pharmaceutical industry-sponsored research. <i>American Journal of Public Health</i> , 2012 , 102, 72-80	5.1	46
33	Do imaging studies performed in physician offices increase downstream utilization?: an empiric analysis of cardiac stress testing with imaging. <i>JACC: Cardiovascular Imaging</i> , 2011 , 4, 630-7	8.4	7
32	Use of fibrates in the United States and Canada. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1217-24	27.4	58
31	A model for dissemination and independent analysis of industry data. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 1593-4	27.4	28
30	Correlation of inpatient and outpatient measures of stroke care quality within veterans health administration hospitals. <i>Stroke</i> , 2011 , 42, 2269-75	6.7	15
29	Determinants of cardiac catheterization use in older Medicare patients with acute myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010 , 3, 54-62	5.8	10
28	State-sponsored public reporting of hospital quality: results are hard to find and lack uniformity. <i>Health Affairs</i> , 2010 , 29, 2317-22	7	12
27	National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010 , 3, 459-67	5.8	133
26	The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. <i>European Journal of Heart Failure</i> , 2010 , 12, 148-55	12.3	32

25	Recent national trends in readmission rates after heart failure hospitalization. <i>Circulation: Heart Failure</i> , 2010 , 3, 97-103	7.6	326
24	Hospital volume and 30-day mortality for three common medical conditions. <i>New England Journal of Medicine</i> , 2010 , 362, 1110-8	59.2	244
23	Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 2141-7	27.4	485
22	Conflicts of interest, authorship, and disclosures in industry-related scientific publications. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 199-200; author reply 201-4	6.4	
21	Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 702-11	15.1	143
20	Beyond insurance coverage: usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. <i>American Heart Journal</i> , 2010 , 160, 115-21	4.9	43
19	Use of administrative claims models to assess 30-day mortality among Veterans Health Administration hospitals. <i>Medical Care</i> , 2010 , 48, 652-8	3.1	14
18	Health care insurance, financial concerns in accessing care, and delays to hospital presentation in acute myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 1392-400	27.4	96
17	Trial publication after registration in ClinicalTrials.gov: a cross-sectional analysis. <i>PLoS Medicine</i> , 2009 , 6, e1000144	11.6	262
16	Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 767-73	27.4	196
15	Exposure to low-dose ionizing radiation from medical imaging procedures. <i>New England Journal of Medicine</i> , 2009 , 361, 849-57	59.2	1001
14	Regional variation in cardiac catheterization appropriateness and baseline risk after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 716-23	15.1	56
13	Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 1800-12	27.4	266
12	Use of ezetimibe in the United States and Canada. <i>New England Journal of Medicine</i> , 2008 , 358, 1819-28	59.2	70
11	Updated estimates of pharmaceutical company payments to physicians in Vermont. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 300, 1998-2000	27.4	4
10	An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008 , 1, 29-37	5.8	391
9	Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1216-23	27.4	47
8	Certificate of need regulation and cardiac catheterization appropriateness after acute myocardial infarction. <i>Circulation</i> , 2007 , 115, 1012-9	16.7	25

7	Cardiac Certificate of Need regulations and the availability and use of revascularization services. <i>American Heart Journal</i> , 2007 , 154, 767-75	4.9	19
6	Effect of blinded peer review on abstract acceptance. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1675-80	27.4	119
5	Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis		1
4	Aggregating Multiple Real-World Data Sources using a Patient-Centered Health Data Sharing Platform: an 8-week Cohort Study among Patients Undergoing Bariatric Surgery or Catheter Ablation of Atrial Fibrillation		2
3	Clinical Evidence Supporting FDA Clearance of First-of-a-Kind Therapeutic Devices via the De Novo Pathway Between 2011 and 2019		1
2	U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018		1
1	Unplanned Hospital Visits after Ambulatory Surgical Care		1